Summit Therapeutics Inc.

NASDAQ: SMMT · Real-Time Price · USD
26.67
0.22 (0.83%)
At close: Aug 15, 2025, 3:59 PM
26.50
-0.64%
After-hours: Aug 15, 2025, 06:23 PM EDT

Summit Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a 704.29K 1.81M
Cost of Revenue
15.01M 2.05M 2.51M n/a
Gross Profit
-15.01M -2.05M -1.81M 1.81M
Operating Income
313K -89.74M -59.63M -86.19M
Interest Income
13.47M 10.4M 1.51M 178.95K
Pretax Income
-221.31M -615.87M -78.78M -88.6M
Net Income
-221.31M -614.93M -78.78M -88.6M
Selling & General & Admin
60.53M 30.27M 26.7M 23.61M
Research & Development
150.78M 59.47M 52M 85.35M
Other Expenses
n/a n/a -5.95M -20.97M
Operating Expenses
211.3M 87.69M 64.28M 88M
Interest Expense
8.69M 16.46M 4.4M 281K
Selling & Marketing Expenses
n/a -2.05M n/a n/a
Cost & Expenses
211.3M 89.74M 72.79M 65.07M
Income Tax Expense
-313K -946K -4.4M n/a
Shares Outstanding (Basic)
718.54M 619.65M 193.34M 92.24M
Shares Outstanding (Diluted)
718.54M 619.65M 193.34M 92.24M
EPS (Basic)
-0.31 -0.99 -0.41 -0.96
EPS (Diluted)
-0.31 -0.99 -0.38 -0.96
EBITDA
-212.85M 1M -73.12M -85.91M
EBIT
-230M -69.61M -74.38M -88.36M
Depreciation & Amortization
17.15M 155.32K 1.26M 2.46M